Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Commentary|Articles|July 6, 2026
NEIAP Delivers a Necessary Network for Ambulatory Care Pharmacists
Fact checked by: Ron Panarotti
Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.
Advertisement
Advertisement
Jennifer Goldman, PharmD, CDCES, BC‑ADM, FCCP, professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences and clinical pharmacist at Well Life, reflects on the New England Institute of Ambulatory Care Pharmacists (NEIAP), an organization she cofounded in 2008 alongside fellow clinician Laura Bogdanski, after realizing how isolating it could be as one of the few ambulatory care pharmacists within a health system.
Related to this article
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Advertisement
Advertisement